蕭英鈞扭轉東洋 連年獲利攀高 2017-03-16 22:05經濟日報 記者黃文奇╱即時報導 東洋董事長蕭英鈞自2014年6月接任董座以來,
Pages
Friday, March 17, 2017
(東洋 蕭英鈞) 啟動 國際結盟: 老驥伏櫪 志在千里
慕德生 張覺前: RFI科技養10萬隻豬
從看天吃飯到靠新科技,農業轉型趨勢不可逆 鄭國強2016-06-14 05:20小中大 圖片來源/台北植物工廠展「一頭豬該來喝幾次水沒來,
感測器應用 監控傳染病 張覺前補充說,「我們有非常好的ICT系統應用在全環控的豬舍裡
科技進步人工變最大成本F-龍燈是全世界前十大農藥供應商,
台灣 臨床試驗成本低廉 成 優勢
安永:全球生技業併購交易活絡 善用法令可節稅 2017-03-16 16:31經濟日報 記者江碩涵╱即時報導 市場充滿不確定性及黑天鵝事件頻出的全球趨勢下,
原創生醫 私募目標: 5000萬元 !!
原創生醫董事會決議通過辦理私募普通股案 中央社新聞 2017/03/16日期:2017年03月16日公司名稱:
麗豐 (陳碧華): 中國 加盟店3278家/ 台灣269家!!
麗豐股息6.5元 配發率70% 2017-03-16 01:40經濟日報 記者江碩涵/台北報導 麗豐-KY(4137)公布去年營收33.6億元、稅後淨利7.
台康 現增~12億 (55元)
台康生技 公司當日重大訊息之詳細內容 本資料由(興櫃公司) 台康生技公司提供序號3發言日期106/03/16發言時間19
健永: CFDA)申請第三期臨床試驗, 正式受理MCS-2前列性肥大 phase III !!
健永生技 發言日期106/03/16發言人何志煌發言人職稱事業處總經理
保瑞藥 聚焦 中樞神經用藥
保瑞法說 投資人熱捧 2017年03月16日 04:10 王克庭 即將掛牌上櫃的生技股保瑞藥業(6472)昨(15)
台灣國際農業開發 董事長(陳郁然): 農產試驗所 聯合團體戰
農業生技拼創新轉型 開發新商機 更新: 2017-03-16【大紀元2017年03月16日訊】(
秀傳 引進治療 腦部震顫 超音波治療儀 (核磁影像導航) !
秀傳醫療體系率先引進「超音波腦神經治療儀」新儀器 記者陳雅芳/彰化報導 2017.03.16 原發性震顫症,是一種常見的腦部疾病,40歲以上也每20人就有
全球牙科併購案熱 人工植牙更熱 台灣廠待機 (亞拓/長庚/台植/全球安聯/鐿鈦/皇亮/鴻君/醫百/巧醫)
牙科醫材5年內 全球成長至368億美元 更新: 2017-03-16【大紀元2017年03月16日訊】
65歲後人腦快速老化基因: TMEM106B的基因
基因變異作怪 腦部老化加快 2017-03-16 17:40:50中央社邁阿密15日綜合外電報導,
傳統醫學 辨證 看 洗腎
洗腎是一輩子的事? 更新:2017年03月17日文/胡乃文(
自我檢視腎臟功能 現今所有腎功能不好和腎衰竭的病,都是在儀器的輔助下「找到」
保養‧加速腎臟病痊癒 如果真的不幸發現腎臟功能不正常,例如喝水覺到脹滿、
(New England Journal of Medicine) 美國未經臨床許可 幹細胞治療失敗案例 (黃斑部病變)
幹細胞療效未獲證實 美3婦失明 發稿時間:2017/03/16(中央社邁阿密15日綜合外電報
Three women blinded after stem cell injections at Broward clinic BY DANIEL CHANG The University of Miami Health System's Bascom Palmer Eye Institute in Miami pictured in October 2014. In this 2012 photo, Dr. Thomas Albini, a professor of clinical ophthalmology at Bascom Palmer Eye Institute, demonstrates an eye exam used on patients to detect signs of macular degeneration. Albini co-wrote an article in this week's New England Journal of Medicine about three women blinded after receiving stem cell injections at a Broward clinic to treat their macular degeneration. When three elderly women with a common age-related eye disease were blinded after receiving stem cell injections at a Broward County clinic in summer 2015, the red flags were apparent to Thomas Albini, a clinical ophthalmologist with the University of Miami Health System's Bascom Palmer Eye Institute. Raising Albini's suspicion were the women's accounts of what had happened: Each had both eyes injected on the same day with stem cells extracted from their body fat. They received little to no follow-up care or evaluation before or after the treatments. And they paid $5,000 each for the procedure."When that all was revealed, I was just in disbelief that this was happening in Broward," said Albini, who helped care for two of the three women and co-wrote an article in this week's New England Journal of Medicine detailing his experience."I knew that things like this could happen in other countries that don't have a sophisticated medical regulatory environment," Albini said Thursday. "But I really was naive to the fact that this could happen in the United States. Then I realized I was just as naive about it as the patients were." The CEO of the Sunrise clinic where the women received the stem cell injections said he believes the article was intended to hurt the company's finances. Albini's article, which was co-written with nine other physicians, exposes what he calls a "loophole" in the U.S. government's oversight of unproven treatments involving stem cells. It also raises questions about whether federal regulators are doing enough to protect patients from risky medical procedures — especially ones that project the false impression that they are government approved. He said he co-wrote the article to alert physicians and patients to the dangers of unwarranted claims about the healing power of stem cells, which Albini said hold great promise but remain largely untested for clinical use."For us to get to the point where we can establish good stem cell therapy," he said, "we have to do good research that is ethical and also scientific. Whatever these patients had, it was neither ethical or scientific." In a written statement issued Thursday, Mike Tomás, CEO of U.S. Stem Cell Clinic, called the NEJM article "old news" and suggested it had been published to challenge the company's most recent financial report that revenue had risen by 38 percent, from $2.2 million in 2015 to $3.03 million in 2016. Tomás, who is a judge for the Miami Herald's annual Business Plan Challenge, also pushed back on suggestions that the clinic's stem cell treatments are unsafe."For nearly 20 years our clinics have conducted more than 7,000 stem cell procedures with less than 0.01 percent adverse reactions reported," he said in the written statement. Tomás declined to comment on the patients, citing federal privacy rules. But he added that the clinic no longer offers eye treatments. The three women, ages 72, 78 and 88, all had macular degeneration, a common eye disease among the elderly that can lead to vision loss. They received the stem cell injections at a clinic in Sunrise that incorporated in 2014 as Regenestem Health and that same year changed its name to U.S. Stem Cell Clinic. Within 36 hours of their treatment at the Broward clinic, two of the three women went to the emergency room at Bascom Palmer for blinding conditions, including increased blood pressure in their eyes, excessive bleeding, retinal detachment and dislocation of their lens. Although the women had moderate vision loss prior to the stem cell treatments, a year later their vision ranged from total blindness to 20/200, which is considered legally blind."The thing that was most alarming when I saw these patients come to Bascom Palmer was the fact that they had this procedure done on both eyes in the same day," Albini said. "If you're going to do something experimental, God gave us two eyes. Do it in one eye at a time. Even commonplace surgeries like cataracts are not performed on both eyes on the same day." Albini spoke to two of the women and believes they might have been misled into thinking that they were participating in a legitimate clinical trial sanctioned by the National Institutes of Health, part of the U.S. Department of Health and Human Services, because at least two of the women said they learned about the stem cell procedure through the website ClinicalTrials.gov — an NIH database that lists publicly and privately supported clinical studies conducted around the world. "They think that when they see that, that it's a rubber stamp of approval from the United States government and somebody has investigated this and said this is a legitimate therapy," he said. "What became quickly apparent to me was that it wasn't clear they had participated in any sort of clinical trial. It didn't sound like a trial in terms of any of the follow up or the evaluation." 550 Number of clinics in the United States offering stem cell therapy for injuries and medical conditions Congress established ClinicalTrials.gov for many reasons, including to provide information about publicly and privately sponsored clinical studies, said Renate Myles, an NIH spokeswoman, in a written statement. The information on the website is provided by study sponsors or principal investigators, but posting on ClinicalTrials.gov does not necessarily reflect endorsement by the NIH, Myles said. "ClinicalTrials.gov does not independently verify the scientific validity or relevance of the trial itself beyond a limited quality control review," she said in the statement. Myles urged patients to talk to their doctors before participating in a study and she noted that the NIH has now posted a more prominent disclaimer on the website. For-profit clinics offering unproven stem cell treatments and making unsubstantiated claims to about their ability to cure a range of medical disorders have proliferated in the United States after first gaining popularity overseas, said Timothy Caufield, a professor of health law and science policy at the University of Alberta in Canada. Many have evaded regulation by the Food and Drug Administration in part because they use stem cells extracted from a patient's own body and because they don't manipulate those cells too much before re-injecting them — a process considered a medical procedure and not a drug."Some of these clinics are making promises about therapies for ALS, for cancer, for autism, for everything," Caufield said, "and of course more for cosmetic procedures, like anti-wrinkle, anti-aging." But, Caufield said, there are very few stem cell therapies approved for clinical use, and that regulation is not preventing the science from advancing. He urged patients to consult the International Society for Stem Cell Research's patient handbook before considering stem cell therapies."There's this perception that there are all these stem cell therapies out there that are close to clinical application that ... are being held back by regulators and if they just step back, there would be all these treatments," he said. "It's just not the case. The science isn't there yet."
慈濟科技大學 無償培訓 種植紅藜 !
紅藜收成農友樂 慈科大無償培訓奏功 2017-03-16 12:15聯合報 記者范振和╱即時報導紅藜收成了!
Class II 醫材 再開放5項可於網購 (血壓壓脈帶/月亮杯/電動輪椅/電動代步車/海水洗鼻器)
新增開放藥商(局)得於通訊交易通路販賣部分第二等級醫療器材 資料來源:食品藥物管理署 建檔日期:2017/03/16 更新時間:2017/03/16有鑑於網際網路、
(台大論文案) 中研院 阮麗蓉/蕭培文 網路連署…審查全台違反學術倫理事件 !
「匡正學術倫理」中研院網路連署中止楊泮池職務 林宥辰 2017年03月16日 13:20 風傳媒 中研院基因體研究中心研究員阮麗蓉、
(台大論文案) 全國教師工會: …台灣學術界也將被國際看不起 (詐騙王國)
學者:楊泮池再不下台 恐釀「學術界禽流感」2017-03-01 10:49聯合報 記者馮靖惠╱即時報導 台大教授郭明良論文案,台大校長楊泮池全身而退。